Ann: RAD201 HER2 nanobody demonstrates favourable tumor targeting, page-10

Given big pharma interest in the radiopharmaceutical space, the six platform (+3-4 more undisclosed within the MD Anderson JV) pipeline and Riccardo previously leading Advanced Accelerator Applications, before and after it was sold to Novartis, you'd think RAD would get taken out if it remains too low for too long. A NASDAQ dual listing would help that process along too in terms of awareness and efficacy corporate activity wise. When you reflect on the current price relative to similar staged CU6 (at 6x mc), its fairly obvious that the gap has to close at some point sooner than later. Exciting entry level here and things to come in 2023 no doubt.